A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder

Phase 3 Completed 1002 enrolled Otsuka Pharmaceutical Development & Commercialization, Inc. Otsuka America Pharmaceutical · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This trial is a 52-week safety study to evaluate the safety of adjunctive aripiprazole in outpatients with major depressive disorder who have experienced an incomplete response to an ongoing antidepressant trial.

Timeline

Start: 2004-09
Primary completion: 2007-11
Completion: 2007-11

Publications

Clayton AH, Baker RA, Sheehan JJ, Cain ZJ, Forbes RA, Marler SV, Marcus R, Berman RM, Thase ME. Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study. BMC Res Notes. 2014 Jul 18;7:459. doi: 10.1186/1756-0500-7-459.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Aripiprazole	Other / unclassified	2 mg	Oral
Comparator	Aripiprazole	Other / unclassified	30 mg	Oral

A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder

Summary

Timeline

Publications

Drugs

Indications